AGN 191103
Latest Information Update: 18 May 2020
At a glance
- Originator Allergan
- Class Antiglaucomas; Antihypertensives
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 03 Oct 2000 No-Development-Reported for Glaucoma in USA (Unknown route)
- 03 Oct 1994 Phase-II clinical trials for Glaucoma in USA (Unknown route)